Chemistry
Explore this Section
- School of Physical and Geographical Sciences >
- Chemistry and Medicinal Chemistry >
- People >
- Tess Phillips
I came to Keele in 2008 as a PDRA working with Prof. Pat Bailey and was appointed to Research Fellow in 2011 and Lecturer in 2013.
I graduated from the University of Cambridge in 1999 with a Masters degree in Natural Sciences, specialising in Chemistry. I stayed on in Cambridge to complete a PhD under the supervision of Prof. Andrew Holmes, investigating how palladium-catalysed reactions can be conducted using environmentally benign carbon dioxide as an alternative to traditional organic solvents.
After completing my PhD in 2003, I spent two and a half years as a medicinal chemist at the Cambridge based biotech company Astex Technology (which became Astex Therapeutics in 2005). During this time I worked on a number of oncology drug discovery projects.
I then moved back into academia, joining The University of Manchester in November 2005, to take up a position as a postdoctoral research associate in Prof. Pat Bailey’s group working on the total synthesis of indole alkaloid natural products.
My research interests are synthetic organic chemistry, medicinal and natural product chemistry and drug discovery.
See our Research Group's website for more information.
Selected Publications
-
2012. Synthesis and evaluation of a novel series of indoloisoquinolines as small molecule anti-malarial leads. Bioorg Med Chem Lett, vol. 22(4), 1770-1773. link> doi> full text>
-
2010. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5956-5969}. doi>
-
2008. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, {4986-4999}. doi>
Full Publications List show
Journal Articles
-
2012. Synthesis and evaluation of a novel series of indoloisoquinolines as small molecule anti-malarial leads. Bioorg Med Chem Lett, vol. 22(4), 1770-1773. link> doi> full text>
-
2010. Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5956-5969}. doi>
-
2010. Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency. JOURNAL OF MEDICINAL CHEMISTRY, vol. 53, {5942-5955}. doi>
-
2009. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, {379-388}. doi>
-
2008. Debenzylation using catalytic hydrogenolysis in trifluoroethanol, and the total synthesis of (-)-raumacline. Tetrahedron letters, vol. 49, 2150-2153.
-
2008. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, {4986-4999}. doi>
-
2004. Palladium catalysed cross-coupling reactions of silylamines. CHEMICAL COMMUNICATIONS, 1976-1977. doi>
-
2001. Palladium-catalysed cross-coupling reactions in supercritical carbon dioxide. CHEMICAL COMMUNICATIONS, 1966-1967. doi>
Chapters
-
2003. Homogeneous catalysis in supercritical carbon dioxide. In Carbon dioxide recovery and utilization. Aresta M (Ed.). Springer Netherlands.
Other
-
2005. Amination of aromatic compounds using transition metal catalysts.
-
2003. Chemical reactions in compressed carbon dioxide using palladium catalysts.
-
2003. Microencapsulated transition metal reagents for reactions in supercritical fluids.
-
2006. Pharmaceutical compounds such as substituted thiazole and isothiazole derivatives and their preparation, pharmaceutical compositions, formulations, and use in prophylaxis or treatment of disease states or conditions mediated by cyclin dependent kinase such as cancers, fungal infections or agricultural use.
-
2005. Preparation of 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators.
-
2006. Preparation of 4-amino-3-pyrazolecarboxamides as CDK2 kinase inhibitors.
-
2006. Preparation of hydroxybenzamides as Hsp90 inhibitors.
-
2006. Preparation of pyrazole derivatives for use in pharmaceutical compositions for the inhibition of cyclin dependent kinases and glycogen synthase kinases.
-
2005. Preparation of pyrazoles as inhibitors of cyclin dependent kinases, glycogen synthase kinase-3 and Aurora kinase.
-
2006. Preparation of thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases.
CHE-00027: General and Organic Chemistry
CHE-00029: General and Organic Chemistry for Health
CHE-10043: Making Organic Molecules
CHE-20001: Organic Synthesis and Chirality
CHE-20005: Drug Design based on Biological Targets
EDU-10049: Organic Reactions
I am active in promoting the understanding of what molecules are through hands-on outreach activities. I run the Molecules Network - a group of schools committed to molecules based science outreach in their communities.
See the Make-it-Molecular website for more information.

